MedPath

Sleep Quality Evolution: Dreem Under CPAP

Not Applicable
Recruiting
Conditions
Sleep Apnea
Obstructive Sleep Apnea
Interventions
Device: Deem 3 Headband
Registration Number
NCT05197855
Lead Sponsor
University Hospital, Grenoble
Brief Summary

Continuous positive airway pressure (CPAP) has a caricatural effect in reducing nocturnal respiratory abnormalities and improving the micro-and macrostructure of sleep. Studies characterizing the improvement of acute sleep parameters after the initiation of CPAP are limited to one or two nights of polysomnographic recording. This is related to the cost of performing these studies with repeated recordings in the laboratory and to the acceptability by patients to perform multiple nights of recordings.

Investigators currently have powerful and reliable methods allowing us to carry out nights at home in the patient's ecosystem, in real-life conditions. The characterization of sleep parameters by these methods is equivalent to a polysomnographic recording.

These technological innovations will allow us to characterize sleep before the initiation of CPAP treatment during several nights performed at home. Investigators will then be able to characterize the kinetics and stability of the improvement of sleep parameters in patients with obstructive sleep apnea syndrome in whom continuous positive airway pressure is initiated.

These data will be original and will serve as exploratory data to judge whether the objective improvement of sleep parameters in the first weeks of treatment is associated with improvement in sleepiness, quality of life, and compliance with treatment.

Detailed Description

This study aims to evaluate the quality of sleep, principally the deep slow-wave sleep (sleep stage N3) before and after the initiation of continuous positive airway pressure (CPAP) treatment.

70 newly diagnosed patients with OSA requiring CPAP treatment, will be included.

For the study, they will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during the first month of CPAP (for a minimum of 9 nights). They will be also equipped with a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.

Patients will also complete questionnaires about their health status before CPAP treatment (at inclusion) and after one month of treatment

These devices will allow the measurements of different parameters: sleep stages, total sleep time, sleep measures derived from sleep stages, snoring, breathing rate, heart rate head movements, arterial hemoglobin oxygen saturation, pulse rate, continuous subcutaneous glucose level, and physical activity data (average daily steps, average distance walked per day).

This will generate interesting data on the sleep parameters and their evolution during the initiation of the CPAP treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Patients newly diagnosed with OSA requiring CPAP treatment
  • Patients able to use a mobile application on a smartphone or tablet
  • Patients with access to a wi-fi internet connection at home
  • Patients agreeing to remote monitoring of CPAP compliance data by the home care provider
  • Patients who have signed consent to participate in the study
  • Subjects affiliated to a social security
Exclusion Criteria
  • Patients already treated for OSA
  • Patients treated with a sleep aid (sleeping medications)
  • Patients with severe chronic obstructive or restrictive lung disease with or without oxygen
  • Patients with unstable cardiovascular disease or severe heart failure requiring hospitalization within the last three months or meeting New York Heart Association criteria, Class III or IV disease
  • Subjects listed in articles L1121-5 to L1121-8: pregnant women, feeding and parturients, subjects deprived of liberty by judicial or administrative decision, persons under legal protection
  • Persons in a period of exclusion from another study or ongoing participation in a drug study
  • Subjects likely, at the investigator's discretion, to be uncooperative or noncompliant with the obligations inherent to participation in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Technological innovations and CPAPDeem 3 HeadbandPatients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.
Primary Outcome Measures
NameTimeMethod
Duration of deep slow-wave sleep (sleep stage N3) before and after initiation of continuous positive airway pressure (CPAP) treatment.7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Time spent on the deep slow-wave sleep stage (stage N3 sleep), recorded by the Dreem 3 headband, from 7 nights before and 9 nights after initiation of CPAP treatment

Secondary Outcome Measures
NameTimeMethod
Average distance walked per day7 nights before CPAP initiation and for a month after CPAP initiation

It will be measured by a Garmin Vivofit 3 pedometer expressed in Kilometer

The percentage of time while sleeping7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Sleep parameter recorded by Dreem 3 headband: sleep efficiency ((TST/TIB) x100)

Evolution of the nocturnal oximetry7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Nocturnal oxygen saturation measured by a pulse oximeter

Duration of the other sleep stages (W, N1, N2 and REM)7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Sleep stages (W, N1, N2 and REM) and total sleep time spent in each sleep stage, recorded by the Dreem 3. All the data units are in minutes

Duration of different sleep times7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Sleep parameters recorded by Dreem 3 headband: sleep times (bedtime, total sleep time (TST), sleep onset delay (SOD),time in bed (TIB), time awake after falling asleep (WASO), final wakefulness time)

The frequence of snoring while sleeping recorded by Dreem 3 headband7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

snoring is expressed in decibel minute recorded by a microphone integrated in the Dreem3

Respiratory rate measurment recorded by Dreem 3 headband7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

It is expressed in breathe per minute recorded accelerometer sensor

Sleep quality assessed by Pittsburg questionnaireAt inclusion and a month after CPAP initiation

The PSQI includes a scoring key for calculating a patient's seven subscores, each of which can range from 0 to 3. The subscores are tallied, yielding a "global" score that can range from 0 to 21. A global score of 5 or more indicates poor sleep quality; the higher the score, the worse the quality.

The frequences of sleep waves during the NREM sleep stage recorded by Dreem 3 headband7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

sleep spindle density expressed in Hertz recorded by the EEG sensors

Evolution of the subcutaneous glucose level7 nights before CPAP initiation and for a month after CPAP initiation

Continuous subcutaneous glucose level (measured by FreeStyle Libre 2 continuous glucose sensor)

Average daily number of steps7 nights before CPAP initiation and for a month after CPAP initiation

It will be measured by a Garmin Vivofit 3 pedometer expressed in steps/day

Severity of insomnia measured by the index sverety of insomnia questionnaireAt inclusion and a month after CPAP initiation

The general ISI score varies between 0 and 28: -7 = No insomnia 8-14 = Sub-clinical insomnia (mild) 15-21 = Clinical insomnia (moderate) 22-28 = Clinical insomnia (severe)

Evolution of the quality of life by the Short Form 36 health survey questionnaireAt inclusion and a month after CPAP initiation

A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Evolution of the compliance of CPAP treatmentFor a month during CPAP treatment

Collection of average CPAP treatment use (in hours/day) provided by telemonitoring

Heart rate measurement while sleepingrecorded by Dreem 3 headband7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Expressed in beats per minute recorded by accelerometer sensor

Evolution of glycemiaAt inclusion and a month after CPAP initiation

Blood glucose level by blood sampling

Evolution of the somnolenceAt inclusion and a month after CPAP initiation

Epworth Sleepiness Score (ESS):

0 = no chance of dozing or falling asleep

1. = low chance of falling asleep

2. = medium chance of falling asleep

3. = high chance of falling asleep

Evolution of the effectiveness of CPAP treatmentFor a month during CPAP treatment

Collection of residual AHI provided by telemonitoring

The position of the head changes while sleeping recorded by Dreem 3 headband7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Head movements are recorded by an accelerometer sensor in the Dreem 3 Headband

Trial Locations

Locations (1)

Grenoble Alpes University Hospital

🇫🇷

Grenoble, France

© Copyright 2025. All Rights Reserved by MedPath